CAPRICOR THERAPEUTICS, INC.CAPREarnings & Financial Report
Capricor Therapeutics is a clinical-stage biotechnology company focused on discovering, developing and commercializing innovative biological therapies including cell and gene therapies for rare diseases, cardiovascular disorders and muscular conditions. It primarily operates in the U.S. market, addressing unmet medical needs for patient groups with limited treatment options.
CAPR Q4 FY2024 Key Financial Metrics
Revenue
$11.1M
Gross Profit
N/A
Operating Profit
$-7.7M
Net Profit
$-7.1M
Gross Margin
N/A
Operating Margin
-69.1%
Net Margin
-63.9%
YoY Growth
-7.9%
EPS
$-0.11
CAPRICOR THERAPEUTICS, INC. Q4 FY2024 Financial Summary
CAPRICOR THERAPEUTICS, INC. reported revenue of $11.1M (down 7.9% YoY) for Q4 FY2024, with a net profit of $-7.1M (down 833.8% YoY) (-63.9% margin).
Key Financial Metrics
| Total Revenue | $11.1M |
|---|---|
| Net Profit | $-7.1M |
| Gross Margin | N/A |
| Operating Margin | -69.1% |
| Report Period | Q4 FY2024 |
CAPRICOR THERAPEUTICS, INC. Annual Revenue by Year
CAPRICOR THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $22.3M).
CAPRICOR THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
CAPRICOR THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $11.1M | -7.9% | $-7.1M | -63.9% |
| Q3 FY2024 | $2.3M | -63.4% | $-12.6M | -555.2% |
| Q2 FY2024 | $4.0M | +1.4% | $-11.0M | -277.0% |
| Q1 FY2024 | $4.9M | +64.3% | $-9.8M | -199.6% |
| Q4 FY2023 | $12.1M | — | $-762.1K | -6.3% |
| Q3 FY2023 | $6.2M | +288.7% | $-6.4M | -103.3% |
| Q2 FY2023 | $3.9M | — | $-7.4M | -188.0% |
| Q1 FY2023 | $3.0M | — | $-7.8M | -260.1% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $3.9M | $6.2M | $12.1M | $4.9M | $4.0M | $2.3M | $11.1M |
| YoY Growth | N/A | N/A | 288.7% | N/A | 64.3% | 1.4% | -63.4% | -7.9% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $53.9M | $46.0M | $37.2M | $58.7M | $49.4M | $38.3M | $93.0M | $170.5M |
| Liabilities | $47.7M | $43.3M | $38.9M | $36.1M | $31.0M | $26.8M | $24.7M | $25.0M |
| Equity | $6.2M | $2.7M | $-1.8M | $22.6M | $18.4M | $11.5M | $68.3M | $145.5M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $4.2M | $-9.4M | $-8.8M | $-11.6M | $-1.3M | $-12.3M | $-11.6M | $-14.8M |